Navigation Links
NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology

SOPHIA ANTIPOLIS, France, Oct. 2 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced the presentation of promising clinical and preclinical results from its collaboration with Ferrer Grupo International at the 21st World Congress of Dermatology, in Buenos Aires, Argentina. These included phase 1 results for NCX 1022, a prototype compound, showing the potential for improved safety and tolerability and preclinical results for a novel, high potency, nitric oxide-donating anti-inflammatory suggesting it could have enhanced anti-inflammatory activity over current dermatology products.

Ennio Ongini, Vice President of Research at NicOx, declared: "We are delighted to present these very promising results with Ferrer at this prestigious scientific meeting. These results highlight the potential of our technology in dermatology and suggest our joint program with Ferrer has the potential to provide more effective drugs to treat chronic skin disorders, which represent an increasing burden on medical services. Furthermore, the clinical data on NCX 1022 suggest that nitric oxide donation may also improve the safety margin over current treatments. We will continue to work closely with Ferrer to bring our promising drug candidate into clinical trials."

NicOx and Ferrer initiated their development program focused on high potency, nitric oxide-donating anti-inflammatory agents, for the treatment of a range of skin disorders (see NOTE), following encouraging results from a phase 1 study for NCX 1022, a lower potency prototype (see top-line results in press release of April 29, 2004). This presentation at the World Congress of Dermatology was the first time these results were presented at a scientific meeting. The results showed that the application of NCX 1022 ointment did not induce skin blanching with there being statistically significantly less skin blanching with NCX 1022 compared with three commonly used marketed products (p<0.001).

In parallel, NicOx and Ferrer jointly presented a series of preclinical results from a novel, high potency, nitric oxide-donating anti-inflammatory compound at the congress, which showed a broader anti-inflammatory activity than commonly used treatments for skin disorders. These results were obtained in a validated preclinical model of skin disorders by following selected biological markers involved in inflammatory pathways (namely pro-inflammatory mediators such as PGE2, cytokines and TNF-alpha). Scientists have proposed a role for nitric oxide in a number of biological processes in the skin.

Antonio Guglietta, Head of Research and Development at Ferrer, commented: "Nitric oxide is thought to play an important role in the physiology of the skin and these new preclinical results suggest nitric oxide-donating anti- inflammatory agents could have improved efficacy over existing treatments. We believe this collaboration with NicOx can lead to the successful development of a more effective and safer treatment for skin disorders."

NOTE: NicOx and Ferrer aim to develop an improved product to treat a range of skin disorders, including Atopic Dermatitis, Psoriasis and Seborrheic Dermatitis, which affect millions of people each year. The severity of these

conditions can vary widely and in the worst cases they can be painful, increase the risk of infection and cause social isolation due to appearance.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide- donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes.

NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer Inc. and Merck & Co., Inc.

NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of Euronext(TM) Paris (segment: Next Economy).

The elements included in this communication may contain forward-looking statements subject to certain risks and uncertainties. Actual results of the company may differ materially from those indicated in the forward-looking statements because of different risk factors described in the company's document de reference.

Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
2. The Past, Present and Future of HLA Typing
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/2/2015)... 2015 TB Alliance and its partners ... medicines in the correct doses. The improved treatments ... set by the World Health Organization (WHO) in ... administer and affordable. The availability of these products ... by UNITAID. ...
(Date:12/1/2015)... and VANCOUVER , Dec. 1, 2015 ... OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today ... on the pre-planned interim futility analysis of the intent-to-treat ... safety issues were identified by the DMC. Both the ... final results are expected in the second half of ...
(Date:12/1/2015)... 01, 2015 ... the "Spinal Muscular Atrophy Market - ... 2015 - 2023" report to their ... announced the addition of the "Spinal ... Growth, Trends, and Forecast 2015 - 2023" ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article published on ... claim against the U.S. Department of Health and Human Services, claiming that any states ... are breaking the clause in the law prohibiting the denial of coverage for pre-existing ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... there are professionals who believe that with innovative technologies and under the right ... patient to get the benefit of a dual-approach to his or her therapeutic ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo ... — a number even greater among Millennials (a whopping one in three aged 18 ... more people who are dissatisfied with their ink. In fact, RealSelf , the ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic ... addition to the devices for sale in the United States. Clarity is a ... 1064 nm Nd:YAG lasers, into a single platform that is easy to own and ...
Breaking Medicine News(10 mins):